Live Breaking News & Updates on ஏரி ப்ளூ மூலதனம்

2 Min Read
FILE PHOTO: The logo of the Carlyle Group is displayed at the company s office in Tokyo, Japan October 17, 2018. REUTERS/Issei Kato
HONG KONG (Reuters) - Chinese biotech company Abbisko Therapeutics Co has raised $123 million from more than a dozen investors, including Carlyle Group and Warburg Pincus, in its latest funding round, the company said on Friday.
Abbisko said in a news release that Carlyle led the latest fundraising with Warburg, OrbiMed, Lake Bleu Capital, and an unnamed Boston-based investor as the joint leading investors.
Other investors include Janchor Partners, Sage Partners, SHC and Greater Bay Area Homeland Development Fund. ....

United States , Warburg Pincus , Kane Wu , Himani Sarkar , Thomson Reuters Trust Principles , Greater Bay Area Homeland Development Fund , Abbisko Therapeutics Co , Temasek Holdings , Carlyle Group , Lake Bleu Capital , Janchor Partners , Sage Partners , Greater Bay Area Homeland Development , Lilly Asia Ventures , Qiming Venture Partners , Hankang Capital , Thomson Reuters Trust , Asia Pacific , Company News , East Asia , Emerging Market Countries , Healthcare Trbc Level 1 , Hong Kong , Diversified Investment Services Trbc Level 4 , Diversified Investment Services Trbc Level 5 , Private Equity Trbc Level 5 ,